Median Effective Dose (ED50) of butorphanol pretreatment for prevention of etomidate induced myoclonus

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900022782

Enrollment

Unknown

Registered

2019-04-25

Start date

2019-05-01

Completion date

Unknown

Last updated

2019-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myoclonus

Interventions

butorphanol pretreatment (B1

B5):intravenous butorphanol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients undergoing selective operation; 2. Aged 18~65 years; 3. ASA I-II; 4. BMI 18~30 kg/m2 5. Sign written informed consent and unwilling to abide by research protocols approved by the investigator.

Exclusion criteria

Exclusion criteria: 1. Pregnancy or breastfeeding; 2. Heart or Liver or kidney disease; 3. Mental or neurological disorders; 4. Opioid abuse; 5. Alcohol abuse history; 6 Subjects has contraindication for butorphanol; 7. Allergy history.

Design outcomes

Primary

Measure	Time frame
myoclonus;	—

Countries

China

Contacts

Public ContactLiu Su

Department of Anesthesiology, Affiliated Hospital of Xuzhou Medical University

150040009@qq.com+86 18118309692

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026